Aerie Pharmaceuticals Inc (AERI) : Partner Fund Management reduced its stake in Aerie Pharmaceuticals Inc by 16.02% during the most recent quarter end. The investment management company now holds a total of 1,966,417 shares of Aerie Pharmaceuticals Inc which is valued at $78,165,076 after selling 375,223 shares in Aerie Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Aerie Pharmaceuticals Inc makes up approximately 2.66% of Partner Fund Management’s portfolio.
Other Hedge Funds, Including , Tudor Investment Corp Et Al added AERI to its portfolio by purchasing 16,990 company shares during the most recent quarter which is valued at $675,353. Aerie Pharmaceuticals Inc makes up approx 0.02% of Tudor Investment Corp Et Al’s portfolio. Laurion Capital Management Lp added AERI to its portfolio by purchasing 24,300 company shares during the most recent quarter which is valued at $910,035. Aerie Pharmaceuticals Inc makes up approx 0.03% of Laurion Capital Management Lp’s portfolio.Granite Point Capital Management boosted its stake in AERI in the latest quarter, The investment management firm added 78,275 additional shares and now holds a total of 134,500 shares of Aerie Pharmaceuticals Inc which is valued at $5,124,450. Aerie Pharmaceuticals Inc makes up approx 4.54% of Granite Point Capital Management’s portfolio.Rice Hall James Associates boosted its stake in AERI in the latest quarter, The investment management firm added 1,909 additional shares and now holds a total of 158,932 shares of Aerie Pharmaceuticals Inc which is valued at $5,645,265. Aerie Pharmaceuticals Inc makes up approx 0.32% of Rice Hall James Associates’s portfolio.
Aerie Pharmaceuticals Inc closed down -1.5 points or -3.55% at $40.7 with 4,55,266 shares getting traded on Monday. Post opening the session at $42.5, the shares hit an intraday low of $40.6 and an intraday high of $43.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals Inc was Initiated by Aegis Capital to “Buy” on Nov 1, 2016. Company shares were Reiterated by RBC Capital Mkts on Oct 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 49 from a previous price target of $48 .H.C. Wainwright Initiated Aerie Pharmaceuticals Inc on Sep 20, 2016 to “Buy”, Price Target of the shares are set at $66.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.